Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Michael Klichinsky"'
Autor:
Daniel O. Kraft, Michael Feldman, Saar Gill, Olga Shestova, Marco Ruella, Mariusz A. Wasik, Michael Klichinsky, Amy Ziober, Carl H. June, Saad S. Kenderian
Patients with Hodgkin lymphoma (HL) who relapse or are refractory to first-line therapy have a poor prognosis and some of these patients require innovative therapeutic approaches. Our group and others have demonstrated the clinical efficacy of anti-C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48cc0bb55c7e0b188c616a93025b4d94
https://europepmc.org/articles/PMC5628114/
https://europepmc.org/articles/PMC5628114/
Autor:
Saar Gill, Mariusz A. Wasik, Michael Klichinsky, Marco Ruella, Carl H. June, J. Joseph Melenhorst, Olga Shestova, Simon F. Lacey, Saad S. Kenderian
Publikováno v:
Blood. 128:2159-2159
Chimeric antigen receptor T cells (CART) hold great promise for the treatment of B cell neoplasms as multiple clinical studies show high complete response rates with anti-CD19 CART. However, widespread clinical use of this novel immunotherapy is limi
Autor:
Saar Gill, Michael Klichinsky, Saad S. Kenderian, Olga Shestova, Reshma Singh, Celeste Richardson, Craig R. Soderquist, Regina M. Young, Miriam Y. Kim, Adam Bagg, Carl H. June, Marco Ruella
Publikováno v:
Blood. 128:766-766
Chemo-refractory acute myeloid leukemia (AML) is associated with poor prognosis and treatment options are extremely limited. Most of these patients are ineligible for allogeneic stem cell transplantation. Chemo-refractory AML is thought to arise due
Autor:
Natalka Kengle, J. Joseph Melenhorst, Saad S. Kenderian, Miriam Y. Kim, Michael Klichinsky, Marco Ruella, Fang Chen, Saar Gill, Carl H. June, Olga Shestova, Simon F. Lacey
Publikováno v:
Blood. 128:652-652
Chimeric antigen receptor T (CART) cell therapy results in impressively high remission rates in B cell neoplasms but is limited by the development of cytokine release syndrome (CRS). CRS is characterized by the development of high-grade fevers, hypot
Autor:
Mariusz A. Wasik, Michael Klichinsky, Sohail Qayyum, Saad S. Kenderian, Anthony R. Mato, Qian Zhang, Michael C. Milone, Michael Kalos, Joseph A. Fraietta, Omkar U. Kawalekar, Xiaobin Liu, Carl H. June, Marco Ruella, Marcela V. Maus, Stephen J. Schuster, Saar Gill, Selene Nunez-Cruz, Olga Shestova, Simon F. Lacey
Publikováno v:
Blood. 126:704-704
Introduction: The bruton tyrosine kinase (BTK) inhibitor ibrutinib demonstrates considerable activity in mantle cell lymphoma (MCL). However, approximately 30% of patients do not respond to this treatment and the therapy invariably leads to drug resi
Autor:
Marco Ruella, Carl H. June, Saar Gill, Olga Shestova, Michael Klichinsky, David L. Porter, Saad S. Kenderian, Miriam Y. Kim
Publikováno v:
Blood. 126:852-852
Chimeric antigen receptor T cell (CART) therapy has developed as a powerful and potentially curative therapy in hematological malignancies over the last few years. CD19 directed CART cells have resulted in impressive complete response rates of ~90% i